Logotype for UnitedHealth Group Incorporated

UnitedHealth Group (UNH) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for UnitedHealth Group Incorporated

Q2 2026 earnings summary

10 Aug, 2026

Executive summary

  • Second quarter 2026 revenues reached $112.0 billion, flat to slightly up year-over-year, with strong performance in Medicare Advantage and Optum Health, while commercial benefits remain pressured by elevated cost trends.

  • Earnings from operations rose 55% to $8.0 billion, driven by improved cost management and favorable reserve development.

  • Adjusted EPS for Q2 was $6.38, up from $4.08 year-over-year; reported EPS was $6.04; net margin was 4.9%.

  • Cash flows from operations totaled $11.1 billion for Q2 and $20.0 billion for the first half, reflecting strong earnings and disciplined working capital management.

  • The organization is focused on modernization, affordability, transparency, and leveraging AI to improve operational efficiency and healthcare experiences.

Financial highlights

  • Total revenues for Q2 were $112 billion; for the first six months, $223.8 billion, up 1% year-over-year.

  • Operating earnings grew 55% to $8 billion; net earnings for the first half were $12.2 billion, up 21% year-over-year.

  • Medical care ratio improved to 86.7% from 89.4% in Q2 2025, aided by $860 million in net favorable prior period medical development.

  • Operating cost ratio rose to 12.7% from 12.3% year-over-year, reflecting investments in technology and community support.

  • Return on equity for the first half was 24.3%, up from 20.6% in 2025.

Outlook and guidance

  • Full-year 2026 adjusted EPS guidance raised to $19.50–$20.00; reported EPS expected at $18.45–$18.95.

  • Operating earnings outlook increased for UnitedHealthcare (at least $12 billion) and Optum Health (at least $2.2 billion).

  • Full-year medical care ratio expected at 88.1% ± 25 bps; operating cost ratio at the higher end of the range due to investments.

  • Commercial margin recovery now expected beyond 2027 due to persistent cost trends.

  • Management expects elevated medical cost trends and competitive pressures to persist.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more